

Claudia C Faria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7783978/publications.pdf>

Version: 2024-02-01

39
papers

4,245
citations

279798

23
h-index

361022

35
g-index

40
all docs

40
docs citations

40
times ranked

5819
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
3	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
4	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
5	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
6	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
7	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
8	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
9	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
10	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
11	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <i>Nature Medicine</i> , 2020, 26, 720-731.	30.7	141
12	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	27.8	129
13	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
14	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. <i>Cancer Research</i> , 2015, 75, 134-146.	0.9	51
15	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
16	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
17	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1190-1194.	1.5	42
18	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40

#	ARTICLE	IF	CITATIONS
19	Genetic alterations in a papillary glioneuronal tumor. <i>Journal of Neurosurgery: Pediatrics</i> , 2008, 1, 99-102.	1.3	33
20	Cadherin Expression and EMT: A Focus on Gliomas. <i>Biomedicines</i> , 2021, 9, 1328.	3.2	30
21	BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas. <i>BMC Cancer</i> , 2018, 18, 1259.	2.6	26
22	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. <i>Oncotarget</i> , 2015, 6, 21718-21729.	1.8	26
23	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
24	Pediatric brain tumors: genetics and clinical outcome. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 263-270.	1.3	23
25	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. <i>Oncotarget</i> , 2015, 6, 3359-3374.	1.8	23
26	The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. <i>Pituitary</i> , 2022, 25, 363-382.	2.9	14
27	Imaging mass spectrometry identifies prognostic ganglioside species in rodent intracranial transplants of glioma and medulloblastoma. <i>PLoS ONE</i> , 2017, 12, e0176254.	2.5	13
28	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11
29	A functional genomics approach to identify pathways of drug resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 146.	5.2	10
30	Pediatric central nervous system tumors: review of a single Portuguese institution. <i>Child's Nervous System</i> , 2016, 32, 1227-1236.	1.1	9
31	Patient-derived models of brain metastases recapitulate human disseminated disease. <i>Cell Reports Medicine</i> , 2022, 3, 100623.	6.5	6
32	<i>Cadherin-13</i> is a novel oncogenic biomarker with prognostic value in glioblastoma. <i>Molecular Oncology</i> , 2022, 16, 2611-2631.	4.6	4
33	Lumbar pseudo-tail associated with dermal sinus – A case report. <i>Neurocirugia</i> , 2017, 28, 294-297.	0.4	3
34	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 453-464.	2.9	2
35	EPEN-08. PHARMACOGENOMICS REVEALS ERBB2 AS A THERAPEUTIC TARGET IN PRIMARY EPENDYMOMA CULTURES. <i>Neuro-Oncology</i> , 2019, 21, ii78-ii79.	1.2	0
36	LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease. <i>Neuro-Oncology Advances</i> , 2021, 3, iii10-iii10.	0.7	0

#	ARTICLE	IF	CITATIONS
37	EPEN-33. PHARMACOGENOMICS REVEALS SYNERGISTIC INHIBITION OF ERBB2 AND PI3K SIGNALING AS A THERAPEUTIC STRATEGY FOR EPENDYMOMA. <i>Neuro-Oncology</i> , 2020, 22, iii314-iii314.	1.2	0
38	How Can Biobanks Help You in Your Research Projects?. <i>Stroke</i> , 2022, , STROKEAHA121036917.	2.0	0
39	The Role of Biobanks in the Fight against COVID-19 Pandemic: The Portuguese Response. <i>Acta Medica Portuguesa</i> , 2021, 35, .	0.4	0